EUCTR2007-003086-40-FR进行中（未招募）不适用
A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
Fondation Charcot Stichting0 个研究点目标入组 20 人开始时间: 2007年11月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.patients with aggressive RR or SP MS who failed to respond to approved immunomodulatory drugs (interferons beta, glatiramer acetate) and who cannot or do not wish to receive mitoxantrone or tysabri.
- •2.patients within =18 and = 55 years of age
- •3.patients with a disease duration of maximum 15 years
- •4.clinically definite RR or SP MS, according to Lublin and Reingold definition and the McDonald criteria
- •5.Expanded Disability Status Scale Score (EDSS) = 2.5 and = 5.5
- •6.patients in the RR phase with a poor prognosis because of frequent (= 2/year) and severe relapses (transient EDSS =3) likely leading to permanent disability or patients in the SP phase with clinical signs or symptoms of rapid progression over the last year equivalent to an increase in EDSS of >/ 1 point
- •7.= 1 gadolinium enhancing lesion(s) at screening
- •8.left ventricular ejection fraction = 50%
- •9.standard laboratory parameters within the normal range, including hematology (lymphocytes > 1000/mm³, ANC (absolute neutrophil count) =2000/ml, thrombocytes =100.000/ml)
- •10.male or female patients:
- •NB: female patients of child-bearing potential should have a negative pregnancy test at the time of inclusion
- •male and female patients within reproductive ages should agree to practice effective contraception during the trial and for 6 months following the last administration of PIX.
- •11. have given written informed consent prior to treatment, with the understanding that consent may be withdrawn at any time without prejudice
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.previous treatment with immunosuppressants (Mitoxantrone or other anthracyclines, Cyclophosphamide, Methotrexate, Azathioprine, rituximab, alemtuzumab …) in the past year
- •2.in case of a recent relapse, the time from start of recovery/end of relapse to study entry should be at least one month
- •3.any corticosteroids or ACTH in the month preceding study entry
- •4.patients with cardiac risk factors: prior history of congestive heart failure, myocardial infarction, uncontrolled ischemic heart disease, hypertension or malignant hemopathy
- •5.patients treated with potential cardiotoxic drugs
- •6.patients who are at medical risks because of systemic disease which might interfere with patient safety (e.g.: impairment of renal or hepatic function, severe infection, alcohol abuse or drug addiction)
- •7.patients with impaired intellectual functions or psychiatric disorders preventing normal cooperation during the trial
- •8.participation in any investigational study within 4 weeks prior to treatment start; patient must have recovered from all side effects of other investigational therapy
- •9.history of, or clinical signs or symptoms suggestive of HIV, HBV, HCV
- •10.any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)EUCTR2007-003086-40-BEFondation Charcot Stichting20
进行中（未招募）
1 期
A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and rituximab in patients with relapsed lymphomas of B- or T- cell phenotypeRelapse of aggressive non-Hodgkin lymphoma of B and T-cell phenotypeMedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0 Level: HLGT Classification code 10025321 Term: Lymphomas non-Hodgkin's T-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-000758-39-FIDepartment of Hematology, Aarhus University Hospital84
进行中（未招募）
1 期
Study to evaluate the safety, pharmacokinetics and anti-tumor activity of pixantrone in pediatric patients with cancerRelapsed or refractory solid tumors (excluding those with CNS tumors) or lymphomaMedDRA version: 19.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2016-004554-14-Outside-EU/EEACTI BioPharma Corp.35
进行中（未招募）
不适用
A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and rituximab in patients with relapsed lymphomas of B- or T-cell phenotype.Relapse of aggressive non-Hodgkin lymphoma of B and T-cell phenotypeMedDRA version: 18.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 18.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-000758-39-SEDepartment of Hematology, Aarhus University Hospital84
进行中（未招募）
1 期
A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and rituximab in patients with relapsed lymphomas of B- or T-cell phenotypeRelapse of aggressive non-Hodgkin lymphoma of B and T-cell phenotypeMedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0 Level: HLGT Classification code 10025321 Term: Lymphomas non-Hodgkin's T-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-000758-39-NLDepartment of Hematology, Aarhus University Hospital84